Physician profile
Mark V Andrews
NPI 1720425838
$758.86
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $445 · 2021: $55.55.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $193.92 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $131.99 | 2020 | |
| Pfizer INC. | $98.49 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $64.24 | 2019-2021 | |
| Allergan, INC. | $52.95 | 2020 | |
| Glaxosmithkline, LLC. | $45.79 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.62 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $24.19 | 2019 | |
| Abbvie INC. | $24.18 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.34 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.96 | 2020 | |
| Genentech USA, INC. | $11.62 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.